Meeting
2023 ASCO Annual Meeting
Prime-boost immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer.
Authors
Mark N. Stein
Department of Medicine and Division of Hematology/Oncology, Columbia University Medical Center, New York, NY
Mark N. Stein , Jessica E. Hawley , Russell Kent Pachynski , Kevin Kayvan Zarrabi , Robert Dreicer , Matthew R. Zibelman , Margaret A. Marshall , Bethan Jones , Vicky Wheeler , Sarah Sebastian , Jennifer Bendall , Katie Anderson , Neal D. Shore , Julie N. Graff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT05617040
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5119)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5119
Abstract #
TPS5119
Poster Bd #
202b
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Results of a phase II trial of docetaxel (DOC), bevacizumab (BEV), and androgen deprivation therapy (ADT) for biochemical relapse (BCR) after definitive local therapy for prostate cancer (PC).
First Author: Rana R. McKay
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.
First Author: Zin Myint
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer.
First Author: David James VanderWeele
Poster
2020 Genitourinary Cancers Symposium
A randomized phase II study of apalutamide (APA), androgen deprivation therapy (ADT), or APA + ADT in patients (pts) with biochemically relapsed (BCR) prostate cancer (PC).
First Author: Rahul Raj Aggarwal